BRM
CVS icon

Boston Research & Management’s CVS Health CVS Stock Holding History

Boston Research & Management’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,539
Closed -$201K – 118
2025
Q4 		$201K Buy
+2,539
New +$200K 0.05% 118
2025
Q1 		– Sell
-33,908
Closed -$1.52M – 117
2024
Q4 		$1.52M Sell
33,908
-27,982
-45% -$1.57M 0.37% 63
2024
Q3 		$3.89M Sell
61,890
-5,956
-9% -$347K 0.91% 50
2024
Q2 		$4.01M Sell
67,846
-462
-0.7% -$28.9K 1.01% 47
2024
Q1 		$5.45M Buy
68,308
+875
+1% +$66.8K 1.35% 29
2023
Q4 		$5.32M Buy
67,433
+2,410
+4% +$172K 1.41% 27
2023
Q3 		$4.54M Buy
65,023
+1,085
+2% +$76.9K 1.34% 29
2023
Q2 		$4.42M Buy
63,938
+2,106
+3% +$150K 1.25% 37
2023
Q1 		$4.59M Buy
61,832
+900
+1% +$75.5K 1.37% 33
2022
Q4 		$5.68M Sell
60,932
-310
-0.5% -$29.9K 1.76% 19
2022
Q3 		$5.84M Sell
61,242
-185
-0.3% -$18.3K 1.99% 12
2022
Q2 		$5.69M Sell
61,427
-1,200
-2% -$117K 1.84% 14
2022
Q1 		$6.34M Sell
62,627
-2,224
-3% -$234K 1.84% 16
2021
Q4 		$6.69M Sell
64,851
-184
-0.3% -$17K 1.83% 20
2021
Q3 		$5.52M Buy
65,035
+850
+1% +$71.2K 1.64% 26
2021
Q2 		$5.36M Buy
64,185
+571
+0.9% +$46.8K 1.62% 26
2021
Q1 		$4.79M Buy
63,614
+238
+0.4% +$17.3K 1.54% 28
2020
Q4 		$4.33M Buy
63,376
+697
+1% +$45.3K 1.51% 28
2020
Q3 		$3.66M Sell
62,679
-1,590
-2% -$98.9K 1.43% 33
2020
Q2 		$4.17M Buy
64,269
+1,352
+2% +$85.1K 1.73% 23
2020
Q1 		$3.73M Sell
62,917
-400
-0.6% -$26.7K 1.87% 25
2019
Q4 		$4.7M Sell
63,317
-1,017
-2% -$71.4K 1.76% 24
2019
Q3 		$4.06M Buy
64,334
+2,121
+3% +$126K 1.6% 33
2019
Q2 		$3.39M Sell
62,213
-929
-1% -$50K 1.37% 39
2019
Q1 		$3.4M Buy
63,142
+10,857
+21% +$670K 1.42% 36
2018
Q4 		$3.42M Buy
52,285
+9,795
+23% +$731K 1.63% 29
2018
Q3 		$3.34M Sell
42,490
-568
-1% -$40.6K 1.53% 33
2018
Q2 		$2.77M Buy
43,058
+4,331
+11% +$285K 1.36% 41
2018
Q1 		$2.41M Buy
38,727
+1,982
+5% +$142K 1.23% 41
2017
Q4 		$2.66M Sell
36,745
-4,847
-12% -$352K 1.34% 38
2017
Q3 		$3.38M Buy
41,592
+6,405
+18% +$507K 1.73% 25
2017
Q2 		$2.83M Buy
35,187
+520
+1% +$41.1K 1.53% 37
2017
Q1 		$2.72M Buy
34,667
+3,290
+10% +$263K 1.48% 36
2016
Q4 		$2.48M Buy
31,377
+520
+2% +$42.1K 1.41% 38
2016
Q3 		$2.75M Buy
30,857
+2,067
+7% +$195K 1.59% 30
2016
Q2 		$2.76M Buy
28,790
+480
+2% +$47.8K 1.67% 28
2016
Q1 		$2.94M Buy
28,310
+1,900
+7% +$185K 1.83% 20
2015
Q4 		$2.58M Buy
26,410
+988
+4% +$96.8K 1.61% 24
2015
Q3 		$2.45M Buy
25,422
+307
+1% +$32.3K 1.61% 26
2015
Q2 		$2.63M Sell
25,115
-630
-2% -$64.4K 1.67% 26
2015
Q1 		$2.66M Sell
25,745
-660
-2% -$66.8K 1.69% 26
2014
Q4 		$2.54M Sell
26,405
-30
-0.1% -$2.64K 1.59% 28
2014
Q3 		$2.1M Sell
26,435
-612
-2% -$48.2K 1.41% 33
2014
Q2 		$2.04M Sell
27,047
-1,278
-5% -$96.6K 1.41% 35
2014
Q1 		$2.12M Sell
28,325
-292
-1% -$20.6K 1.56% 29
2013
Q4 		$2.05M Sell
28,617
-667
-2% -$42.9K 1.57% 32
2013
Q3 		$1.66M Sell
29,284
-378
-1% -$22.5K 1.4% 39
2013
Q2 		$1.7M Buy
+29,662
New +$1.72M 1.51% 31

Other funds holding CVS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Boston Research & Management's CVS Position: Q1 2026 in Review

Boston Research & Management sold out of CVS Health (CVS) in Q1 2026, closing a stake of 2,539 shares — an estimated $201K sold.

Boston Research & Management first reported a position in CVS in Q2 2013 and held it in 48 quarters. The position peaked at $6.69M in Q4 2021. 1,865 funds tracked by Wall St. Rank hold CVS as of Q1 2026.

  • Boston Research & Management reported no remaining CVS Health position as of Q1 2026 after selling out during the quarter.
  • Boston Research & Management sold 2,539 CVS Health shares in Q1 2026, an estimated $201K.
  • Boston Research & Management first reported a position in CVS Health in Q2 2013 and held it in 48 quarters.
  • Boston Research & Management's CVS Health position peaked at $6.69M in Q4 2021.
  • 1,865 funds tracked by Wall St. Rank held CVS Health as of Q1 2026.

Based on Boston Research & Management's 13F filing for Q1 2026, filed 10 Apr 2026.